Panacea Biotec Ltd (PANACEABIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 531349 | NSE: PANACEABIO | Pharmaceuticals & Drugs | Small Cap

Panacea Biotec Share Price

343.25 -1.50 -0.44%
as on 05-Dec'25 15:26

Panacea Biotec Ltd (PANACEABIO) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 531349 | NSE: PANACEABIO | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Panacea Biotec

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Panacea Biotec stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
2,111.6 Cr.
52-wk low:
282.2
52-wk high:
581

Is Panacea Biotec Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Panacea Biotec: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Panacea Biotec Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 10.2%1.5%3%11.5%1.1%-0.7%-16.1%-11.4%4.1%-2.1%-
Value Creation
Index
-0.3-0.9-0.8-0.2-0.9-1.1-2.2-1.8-0.7-1.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 647530574444490344236257360310379
Sales YoY Gr.--18.1%8.3%-22.7%10.3%-29.8%-31.5%9.2%39.9%-13.8%-
Adj EPS -4.6-6.6-11.1-32.1-19.8-2.7-15.2-14.90.3-2.6-4.1
YoY Gr.-NANANANANANANANA-870.6%-
BVPS (₹) 18.574.463.468.3140.58367.853.253.751.347.6
Adj Net
Profit
-28.2-40.6-67.7-196-121-16.6-93.2-912.1-16-25
Cash Flow from Ops. 97.9104172107-82.938.3-52.7-10.733.13.9-
Debt/CF from Ops. 10.49.95.66.4-0.81.7-1.6-9.53.858-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -7.9%-8.8%9.6%-13.8%
Adj EPS NANANA-870.6%
BVPS12%-18.3%-8.9%-4.6%
Share Price 8.4% 9.9% 34% -23.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-5.2-8.2-16-48.7-18.5-2.4-20.2-24.60.6-5-8.3
Op. Profit
Mgn %
18.714.715.2-29.58.20.2-30.6-24.23.9-2.2-5.3
Net Profit
Mgn %
-4.4-7.7-11.8-44.2-24.8-4.8-39.6-35.40.6-5.2-6.6
Debt to
Equity
7.82.22.51.70.10.10.20.30.40.70.6
Working Cap
Days
311391359666651576582549393397171
Cash Conv.
Cycle
2647-81-39-207235-1814-33

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Panacea Biotec Ltd.

Standalone Consolidated
TTM EPS (₹) -4.1 -1.2
TTM Sales (₹ Cr.) 379 604
BVPS (₹.) 47.6 134.9
Reserves (₹ Cr.) 286 820
P/BV 7.24 2.56
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 282.15 / 581.00
All Time Low / High (₹) 3.35 / 581.00
Market Cap (₹ Cr.) 2,112
Equity (₹ Cr.) 6.1
Face Value (₹) 1
Industry PE 40.7

Management X-Ray of Panacea Biotec:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Panacea Biotec - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Panacea Biotec

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales647530574444490344236257360310
Operating Expenses 534461493591480343308320345317
Manufacturing Costs63633640324379506768
Material Costs214169197180151176112163142103
Employee Cost 1401321371421235973718797
Other Costs 117971232291746444365049
Operating Profit 1136981-147100-73-6314-7
Operating Profit Margin (%) 17.4%13.1%14.2%-33.0%2.1%0.1%-30.9%-24.4%3.9%-2.2%
Other Income 2654188442113342517
Interest 11510410310514787101415
Depreciation 71665754272726242120
Exceptional Items 50-380334-1500000
Profit Before Tax 1-84-6137-136-13-94-634-26
Tax 1-1111111720251-11
Profit After Tax 1-73-7227-153-14-94-884-15
PAT Margin (%) 0.1%-13.7%-12.5%6.0%-31.3%-4.2%-39.7%-34.1%1.0%-4.9%
Adjusted EPS (₹)0.1-11.9-11.74.3-25.0-2.4-15.3-14.30.6-2.5
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 540456388418861508415326329314
Share Capital 22666666666
Reserves 518450382412855502409320323308
Minority Interest0000000000
Debt997934765158646284102125228
Long Term Debt77971457188606284102125161
Short Term Debt218220194694000068
Trade Payables17422724278136124145129116165
Others Liabilities 267304427939247267289338355174
Total Liabilities 1,9781,9201,8221,5931,307962933895925881

Fixed Assets

Gross Block1,5181,5371,5431,088864826865852827837
Accumulated Depreciation531595652591416428449467470489
Net Fixed Assets 988942891496447398416385357348
CWIP 192837341312897119
Investments 3953453453300000
Inventories137141149439987129116108152
Trade Receivables14217614225183523121121
Cash Equivalents 97128618943431262
Others Assets 2882822461,015676339321310340178
Total Assets 1,9781,9201,8221,5931,307962933895925881

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 98104172107-8338-53-11334
PBT 1-84-6137-136-13-94-634-26
Adjustment 133184160-682053236102730
Changes in Working Capital -58-373137-1442064341
Tax Paid 216-00-8-1-1-1-2-1
Cash Flow From Investing Activity 23-18-3-8-19-37402-47-61
Capex -2-24-15-514-11-61-69-53
Net Investments 24-1-1-4-37-3044-114-15
Others 17131532287
Cash Flow From Financing Activity -129-91-164-98109-71091390
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -39-16-29-16182118172125
Interest Paid -61-94-109-64-39-4-9-8-9-3
Dividend Paid 0000000000
Others -2919-26-19-34-400068
Net Cash Flow -8-5608-6-31-133

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)0.77-25.52-17.036.59-23.93-2.11-20.27-23.641.08-4.74
ROCE (%)10.151.482.9611.511.09-0.7-16.14-11.364.08-2.13
Asset Turnover Ratio0.320.280.310.260.350.310.250.280.40.34
PAT to CFO Conversion(x)98N/AN/A3.96N/AN/AN/AN/A8.25N/A
Working Capital Days
Receivable Days6810710169152845251219
Inventory Days789392795198167173113152
Payable Days307433434325259269438307316499

Panacea Biotec Ltd Stock News

Panacea Biotec Ltd FAQs

The current trading price of Panacea Biotec on 05-Dec-2025 15:26 is ₹343.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Panacea Biotec stood at ₹2,111.6.
The latest P/E ratio of Panacea Biotec as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Panacea Biotec as of 04-Dec-2025 is 7.24.
The 52-week high of Panacea Biotec is ₹581.0 and the 52-week low is ₹282.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Panacea Biotec is ₹379.4 ( Cr.) .

About Panacea Biotec Ltd

The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2006), as well as among the top 50 pharmaceutical companies (as per ORG IMS July 2006) of India.

The company has been granted patents across countries like USA, U.K., France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, The Netherlands, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea and China are among others.

Collaboration/ Strategic alliances The company has collaborated with Cambridge Biostability, U.K to develop thermo stable vaccines.

It has collaborated with National Institute of Immunology, India for Japanese Encephalitis candidate vaccine.

PBL has entered in strategic alliance with Biotech Consortium India to develop, manufacture and market of Anthrax vaccine.

The company has entered into an in-licensing arrangement with National Institute of Health, USA for use of a peptide based product for generation of hair follicles and hair growth.

The company has collaborated with Netherlands Vaccine Institute for inactivated polio vaccine.

It has collaborated with NRDC- India for Foot & Mouth Disease vaccine for veterinary use and Bio Farma-Indonesia for Measles vaccine.

The exclusive products based on patented Drug Delivery System include Panimun Bioral (Cyclosporine), Willgo, ThankGod (for comprehensive management of haemorrohoids), Xeed (anti-tubercular FDC with innovative Drug Delivery for optimum bioavailability of Rifampicin), Nimulid Safeinject, Nimulid MD, Nimulid Transgel. 

Commencing fiscal 2008, the company plans for international marketing of novel NDDS based pharmaceutical formulation products to the international markets, like USA, U.K., Germany, France, Latin American countries and Italy through marketing collaborations and are on the look out for partners for distribution & marketing.

Business areas Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). The company has a team of 200 scientists working on different aspect of research across its four R&D centers.

Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. It is obtaining pre-qualifications for others vaccines. The company markets its vaccines through Chiron Panacea Vaccines, this is a 50:50 joint venture with Novartis Vaccines, U.K

Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant.

Panacea Biotec in 2009 signed an agreement with Popular Pharma for technology transfer, marketing and distribution of vaccines. Popular Pharma is engaged in manufacturing life saving drugs and has presence in various countries.

In 2010 Panacea Biotech's Baddi unit gets US FDA approval
In 2011 PanaceBiotec - Panacea Biotec Launches - PacliALL
In 2012 Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria
PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit
PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical
Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×